Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Betamethasone dipropionate; calcipotriene - Generic Drug Details

« Back to Dashboard
Betamethasone dipropionate; calcipotriene is the generic ingredient in three branded drugs marketed by Leo Pharma As, Tolmar, and Perrigo Israel, and is included in five NDAs. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

This ingredient has sixty-six patent family members in thirty-one countries.

There are sixty-five drug master file entries for betamethasone dipropionate; calcipotriene. One supplier is listed for this compound.

Summary for Generic Name: betamethasone dipropionate; calcipotriene

Drug Master File Entries: see list65
Suppliers / Packaging: see list1
Drug Prices:see low prices

Pharmacology for Ingredient: betamethasone dipropionate; calcipotriene

Clinical Trials for: betamethasone dipropionate; calcipotriene

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Leo Pharma As
betamethasone dipropionate; calcipotriene hydrate
OINTMENT;TOPICAL021852-001Jan 9, 2006RXYes6,753,013Jan 27, 2020Y
Leo Pharma As
betamethasone dipropionate; calcipotriene
AEROSOL, FOAM;TOPICAL207589-001Oct 16, 2015RXYes6,753,013Jan 27, 2020Y
Perrigo Israel
betamethasone dipropionate; calcipotriene hydrate
OINTMENT;TOPICAL200174-001Dec 12, 2014RXNo
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: betamethasone dipropionate; calcipotriene

Country Document Number Estimated Expiration
Japan2002542293<disabled in preview>
Israel145983<disabled in preview>
Czech Republic20013739<disabled in preview>
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.